Here we found two EGFR ECD mutations (A289D and R324L), one HER2 ECD mutation (S310Y), one HER2 transmembrane domain mutation (V659E) and no ERBB3 activating mutations, suggesting that oncogenic driver mutations in non-EGFR or HER2 kinase domain of ERBB family genes do exist, but in a very small proportion of Chinese lung adenocarcinoma patients. This evidence concerns the gene ERBB2 and lung adenocarcinoma.